Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.
Read More…
Industry, Sector and Symbol
Industry Metal mining
Sub-IndustryN/A
SectorMedical
Phone310-598-5410
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$13.98 million
Profitability
Miscellaneous
Employees16
Next Earnings Date11/6/2019 (Estimated)
OptionableNot Optionable
Opiant Pharmaceuticals (NASDAQ:OPNT) Frequently Asked Questions
What is Opiant Pharmaceuticals' stock symbol?
Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT."
How were Opiant Pharmaceuticals' earnings last quarter?
Opiant Pharmaceuticals Inc (NASDAQ:OPNT) posted its quarterly earnings data on Thursday, August, 8th. The technology company reported $0.31 earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.55) by $0.86. The technology company earned $6.78 million during the quarter, compared to analysts' expectations of $3.91 million. Opiant Pharmaceuticals had a negative net margin of 11.78% and a negative return on equity of 12.74%. View Opiant Pharmaceuticals' Earnings History.
When is Opiant Pharmaceuticals' next earnings date?
What price target have analysts set for OPNT?
2 equities research analysts have issued 1-year target prices for Opiant Pharmaceuticals' stock. Their predictions range from $42.00 to $42.00. On average, they expect Opiant Pharmaceuticals' stock price to reach $42.00 in the next year. This suggests a possible upside of 180.0% from the stock's current price. View Analyst Price Targets for Opiant Pharmaceuticals.
What is the consensus analysts' recommendation for Opiant Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opiant Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Opiant Pharmaceuticals.
What are Wall Street analysts saying about Opiant Pharmaceuticals stock?
Here are some recent quotes from research analysts about Opiant Pharmaceuticals stock:
- 1. Northland Securities analysts commented, "We anticipate 2Q royalties from NARCAN of ~$6.165MM. Opiant is slated to report 2Q results post-close on August 8th, and we anticipate a strong topline and bottom line beat." (8/2/2019)
- 2. Cantor Fitzgerald analysts commented, "We reiterate our OW rating on Opiant, which is developing treatments focused on multiple addictions as well as a new product for opioid overdose. As the company advances its pipeline, and provided the data are positive, which we believe they should be, we expect investors to begin to appreciate the market potential of Opiant’s pipeline, and that should drive the stock higher. Valuation Summary We use a blend of DCF and EV/EBITDA to arrive at our $32 price target." (8/28/2018)
Has Opiant Pharmaceuticals been receiving favorable news coverage?
Media stories about OPNT stock have been trending negative on Tuesday, according to InfoTrie. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Opiant Pharmaceuticals earned a media sentiment score of -2.3 on InfoTrie's scale. They also assigned news headlines about the technology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Opiant Pharmaceuticals.
Who are some of Opiant Pharmaceuticals' key competitors?
Some companies that are related to Opiant Pharmaceuticals include Mountain Province Diamonds (MPVD), Fission Uranium (FCUUF), Amerigo Resources (ARREF), Jaguar Mining (JAGGF), Rubicon Minerals (RBYCF), Wealth Minerals (WMLLF), Atlatsa Resources (ATLRF), Santa Fe Gold (SFEG), Alderon Iron Ore (AXXDF), Silver Bull Resources (SVBL), Pacific Booker Minerals (PBMLF), Quantum Materials (QTMM), Bullfrog Gold (BFGC), Avalon Advanced Materials (AVLNF) and Royal Standard Minerals Inc USA (RYSMF).
What other stocks do shareholders of Opiant Pharmaceuticals own?
Who are Opiant Pharmaceuticals' key executives?
Opiant Pharmaceuticals' management team includes the folowing people:
- Dr. Roger Crystal, CEO & Director (Age 43)
- Mr. David D. O'Toole, Chief Financial Officer (Age 60)
- Dr. Phil Skolnick, Chief Scientific Officer (Age 72)
- Mr. Kevin Andrew Pollack Esq., J.D., M.B.A., Advisor (Age 49)
- Mr. Quan Vu, VP of Corp. Devel.
Who are Opiant Pharmaceuticals' major shareholders?
Opiant Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Stonepine Capital Management LLC (8.04%), Morgan Stanley (0.55%), BlackRock Inc. (0.53%), Granite Investment Partners LLC (0.37%) and Advisor Group Inc. (0.12%). Company insiders that own Opiant Pharmaceuticals stock include Ann L Macdougall, David D O'toole, Geoffrey Wolf, Phil Skolnick, Roger Crystal and Thomas T Thomas. View Institutional Ownership Trends for Opiant Pharmaceuticals.
Which major investors are selling Opiant Pharmaceuticals stock?
OPNT stock was sold by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC. Company insiders that have sold Opiant Pharmaceuticals company stock in the last year include Phil Skolnick and Roger Crystal. View Insider Buying and Selling for Opiant Pharmaceuticals.
Which major investors are buying Opiant Pharmaceuticals stock?
OPNT stock was acquired by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Morgan Stanley, BlackRock Inc. and Advisor Group Inc.. Company insiders that have bought Opiant Pharmaceuticals stock in the last two years include Ann L Macdougall and David D O'toole. View Insider Buying and Selling for Opiant Pharmaceuticals.
How do I buy shares of Opiant Pharmaceuticals?
Shares of OPNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Opiant Pharmaceuticals' stock price today?
One share of OPNT stock can currently be purchased for approximately $15.00.
How big of a company is Opiant Pharmaceuticals?
Opiant Pharmaceuticals has a market capitalization of $60.62 million and generates $13.98 million in revenue each year. The technology company earns $-21,190,000.00 in net income (profit) each year or ($7.10) on an earnings per share basis. Opiant Pharmaceuticals employs 16 workers across the globe.View Additional Information About Opiant Pharmaceuticals.
What is Opiant Pharmaceuticals' official website?
How can I contact Opiant Pharmaceuticals?
Opiant Pharmaceuticals' mailing address is 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401. The technology company can be reached via phone at 310-598-5410 or via email at [email protected]
MarketBeat Community Rating for Opiant Pharmaceuticals (NASDAQ OPNT)
MarketBeat's community ratings are surveys of what our community members think about Opiant Pharmaceuticals and other stocks. Vote "Outperform" if you believe OPNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
